REFERENCES
1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Correction: projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:4006.
2. Kim NJ, Cravero A, VoPham T, et al. Addressing racial and ethnic disparities in US liver cancer care. Hepatol Commun 2023;7:e00190.
3. Bharmal N, Derose KP, Felician MF, Weden MM. Understanding the upstream social determinants of health. Available from: https://www.rand.org/pubs/working_papers/WR1096.html [Last accessed on 15 Jan 2024].
4. Liu JJ, De Cuir N, Kia L, Issaka RB. Towards health equity: the urgent need for upstream intervention studies in gastroenterology and hepatology. Lancet Gastroenterol Hepatol 2022;7:203-4.
5. Gehlert S, Sohmer D, Sacks T, Mininger C, McClintock M, Olopade O. Targeting health disparities: a model linking upstream determinants to downstream interventions. Health Aff 2008;27:339-49.
6. Diaz A, O'Reggio R, Norman M, Thumma JR, Dimick JB, Ibrahim AM. Association of historic housing policy, modern day neighborhood deprivation and outcomes after inpatient hospitalization. Ann Surg 2021;274:985-91.
7. Diaz A, Valbuena VSM, Dimick JB, Ibrahim AM. Association of neighborhood deprivation, race, and postoperative outcomes: improvement in neighborhood deprivation is associated with worsening surgical disparities. Ann Surg 2023;277:958-63.
8. Moazzam Z, Woldesenbet S, Endo Y, et al. Association of historical redlining and present-day social vulnerability with cancer screening. J Am Coll Surg 2023;237:454-64.
9. Munir MM, Woldesenbet S, Endo Y, et al. Disparities in socioeconomic factors mediate the impact of racial segregation among patients with hepatopancreaticobiliary cancer. Ann Surg Oncol 2023;30:4826-35.
10. Ashing KT, Jones V, Bedell F, Phillips T, Erhunmwunsee L. Calling attention to the role of race-driven societal determinants of health on aggressive tumor biology: a focus on black americans. Available from: https://ascopubs.org/doi/full/10.1200/OP.21.00297 [Last accessed on 15 Jan 2024].
11. Lin JS, Hoffman L, Bean SI, et al. Addressing racism in preventive services: methods report to support the us preventive services task force. JAMA 2021;326:2412-20.
12. Obeng-Gyasi S, Pawlik TM. Social determinants of health in surgery: a primer for the practicing surgeon. Elsevier Health Sciences; 2023.
13. Adler NE, Glymour MM, Fielding J. Addressing social determinants of health and health inequalities. JAMA 2016;316:1641-2.
14. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33.
15. Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer 2016;122:2512-23.
16. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18:223-38.
17. El-Serag HB, Kanwal F, Feng Z, Marrero JA, Khaderi S, Singal AG. Texas Hepatocellular Carcinoma Consortium. Risk factors for cirrhosis in contemporary hepatology practices-findings from the texas hepatocellular carcinoma consortium cohort. Gastroenterology 2020;159:376-7.
18. Fischer GE, Bialek SP, Homan CE, Livingston SE, McMahon BJ. Chronic liver disease among alaska-native people, 2003-2004. Am J Gastroenterol 2009;104:363-70.
19. McMahon BJ, Nolen LD, Snowball M, et al. HBV genotype: a significant risk factor in determining which patients with chronic HBV Infection should undergo surveillance for HCC: the hepatitis B Alaska study. Hepatology 2021;74:2965-73.
20. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska natives. Am J Epidemiol 1993;138:544-9.
21. Bradley H, Hall EW, Rosenthal EM, Sullivan PS, Ryerson AB, Rosenberg ES. Hepatitis C virus prevalence in 50 U.S. states and D.C. by sex, birth cohort, and race: 2013-2016. Hepatol Commun 2020;4:355-70.
22. Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One 2018;13:e0204412.
23. Kim D, Li AA, Perumpail BJ, et al. Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology 2019;69:1064-74.
24. People born outside of the United States and viral hepatitis. Available from: https://www.cdc.gov/hepatitis/populations/Born-Outside-United-States.htm [Last accessed on 12 Jan 2024].
25. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 2018;68:723-50.
26. Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology 2021;73:713-25.
27. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-41.
28. Perumalswami PV, Wyatt B, Bowman CA, et al. Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C. Cancer Med 2022;11:1995-2005.
29. Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol 2019;17:766-73.
30. Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health 2015;105:e60-76.
31. Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, et al. Provider attitudes toward risk-based hepatocellular carcinoma surveillance in patients with cirrhosis in the United States. Clin Gastroenterol Hepatol 2022;20:183-93.
32. Barzi A, Zhou K, Wang S, Dodge JL, El-Khoueiry A, Setiawan VW. Etiology and outcomes of hepatocellular carcinoma in an ethnically diverse population: the multiethnic cohort. Cancers 2021;13:3476.
33. Estevez J, Yang JD, Leong J, et al. Clinical features associated with survival outcome in African-American patients with hepatocellular carcinoma. Am J Gastroenterol 2019;114:80-8.
34. Pomenti S, Gandle C, Abu Sbeih H, et al. Hepatocellular carcinoma in hispanic patients: trends and outcomes in a large United States cohort. Hepatol Commun 2020;4:1708-16.
35. Moten AS, Fagenson AM, Pitt HA, Lau KN. Recent improvements in racial disparity in the treatment of hepatocellular carcinoma: how times have changed. J Gastrointest Surg 2021;25:2535-44.
36. Kangas-Dick A, Gall V, Hilden P, et al. Disparities in utilization of services for racial and ethnic minorities with hepatocellular carcinoma associated with hepatitis C. Surgery 2020;168:49-55.
37. Rich NE, Hester C, Odewole M, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2019;17:551-9.e1.
38. McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis 2010;14:461-76.
39. Rizzo A, Dadduzio V, Ricci AD, et al. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2022;31:371-8.
40. Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol 2020;16:2587-9.
41. Santoni M, Rizzo A, Mollica V, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol 2022;170:103596.
42. Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in cancer incidence and trends among american indians and alaska natives in the united states, 2010-2015. Cancer Epidemiol Biomarkers Prev 2019;28:1604-11.
43. Inadomi JM, Issaka RB, Green BB. What multilevel interventions do we need to increase the colorectal cancer screening rate to 80%? Clin Gastroenterol Hepatol 2021;19:633-45.
44. Samant H, Kohli K, Patel K, et al. Clinical presentation of hepatocellular carcinoma in african americans vs. caucasians: a retrospective analysis. Pathophysiology 2021;28:387-99.
45. Jones PD, Scheinberg AR, Muenyi V, Gonzalez-Diaz J, Martin PM, Kobetz E. Socioeconomic and survival differences among minorities with hepatocellular carcinoma in Florida. J Hepatocell Carcinoma 2019;6:167-81.
46. Poulson MR, Blanco BA, Geary AD, et al. The role of racial segregation in treatment and outcomes among patients with hepatocellular carcinoma. HPB 2021;23:854-60.
47. Zhou K, Pickering TA, Gainey CS, et al. Presentation, management, and outcomes across the rural-urban continuum for hepatocellular carcinoma. JNCI Cancer Spectr 2021;5:pkaa100.
48. Azap RA, Hyer JM, Diaz A, Paredes AZ, Pawlik TM. Association of county-level vulnerability, patient-level race/ethnicity, and receipt of surgery for early-stage hepatocellular carcinoma. JAMA Surg 2021;156:197-9.
49. Diaz A, Burns S, Paredes AZ, Pawlik TM. Accessing surgical care for pancreaticoduodenectomy: patient variation in travel distance and choice to bypass hospitals to reach higher volume centers. J Surg Oncol 2019;120:1318-26.
50. Munir MM, Endo Y, Woldesenbet S, et al. Variations in travel patterns affect regionalization of complex cancer surgery in California. Ann Surg Oncol 2023;30:8044-53.
51. Smith AK, Shara NM, Zeymo A, et al. Travel patterns of cancer surgery patients in a regionalized system. J Surg Res 2015;199:97-105.
52. Diaz A, Schoenbrunner A, Pawlik TM. Trends in the geospatial distribution of adult inpatient surgical cancer care across the United States. J Gastrointest Surg 2020;24:2127-34.
53. Diaz A, Chavarin D, Paredes AZ, Tsilimigras DI, Pawlik TM. Association of neighborhood characteristics with utilization of high-volume hospitals among patients undergoing high-risk cancer surgery. Ann Surg Oncol 2021;28:617-31.
54. Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr 2016;5:43-52.
55. Nathan H, Cameron JL, Choti MA, Schulick RD, Pawlik TM. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg 2009;208:528-38.
56. Hyer JM, Tsilimigras DI, Diaz A, et al. High social vulnerability and "textbook outcomes" after cancer operation. J Am Coll Surg 2021;232:351-9.
57. Flores YN, Datta GD, Yang L, et al. Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev 2021;30:1193-9.
58. Singal AG, Tiro JA, Murphy CC, et al. Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis. Clin Gastroenterol Hepatol 2021;19:987-95.e1.
59. Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2022;76:195-201.
60. Gani F, Diaz A, Johnston FM, Pawlik TM, Canner JK. Comparison of clinical and financial outcomes at urban and rural hospitals among patients receiving inpatient surgical care. J Am Coll Surgeons 2018;227:S140-1.
61. Abbas A, Diaz A, Obeng-Gyasi S, et al. Disparity in clinical trial participation among patients with gastrointestinal cancer. J Am Coll Surg 2022;234:589-98.
62. Alterio RE, Ju MR, Wang SC, Mansour JC, Yopp A, Porembka MR. Socioeconomic and racial/ethnic disparities in receipt of palliative care among patients with metastatic hepatocellular carcinoma. J Surg Oncol 2021;124:1365-72.
63. Scaglione S, Adams W, Caines A, et al. Association between race/ethnicity and insurance status with outcomes in patients with hepatocellular carcinoma. Dig Dis Sci 2020;65:1669-78.
64. Lee RM, Gamboa AC, Turgeon MK, et al. Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: an analysis from the United States safety net collaborative. Surg Oncol 2020;35:120-5.
65. Wang J, Ha J, Lopez A, Bhuket T, Liu B, Wong RJ. Medicaid and uninsured hepatocellular carcinoma patients have more advanced tumor stage and are less likely to receive treatment. J Clin Gastroenterol 2018;52:437-43.
66. Adler Jaffe S, Myers O, Meisner ALW, Wiggins CL, Hill DA, McDougall JA. Relationship between insurance type at diagnosis and hepatocellular carcinoma survival. Cancer Epidemiol Biomarkers Prev 2020;29:300-7.
67. Diaz A, Chavarin D, Paredes AZ, Pawlik TM. Utilization of high-volume hospitals for high-risk cancer surgery in california following medicaid expansion. J Gastrointest Surg 2021;25:1875-84.
68. Diaz A, Pawlik TM. Insurance status and high-volume surgical cancer: access to high-quality cancer care. Cancer 2021;127:507-9.
69. Asemota J, Oladunjoye O, Babalola A, et al. Comparison of hepatocellular carcinoma in hispanic and non-hispanic patients. Cureus 2021;13:e14884.
70. Cha AE, Cohen RA. Demographic variation in health insurance coverage:United States, 2020. Natl Health Stat Report 2022;169:1-15.
71. Branch B, Conway D. Health insurance coverage by race and hispanic origin: 2021. Available from: https://www.census.gov/content/dam/Census/library/publications/2022/acs/acsbr-012.pdf [Last accessed on 15 Jan 2024].
72. Chavarin D, Diaz A, Paredes A, Pawlik TM. High-risk cancer operations in california after medicaid expansion. J Am Coll Surgeons 2020;231:S139-40.
73. Moss HA, Wu J, Kaplan SJ, Zafar SY. The affordable care act's medicaid expansion and impact along the cancer-care continuum: a systematic review. J Natl Cancer Inst 2020;112:779-91.
